Spectinomycin adverse reactions: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
 
Line 5: Line 5:
==Adverse Reactions==
==Adverse Reactions==


The following reactions were observed during the single dose clinical trials: soreness at the injection site, urticaria, dizziness, nausea, chills, fever and insomnia.
The following reactions were observed during the single dose clinical trials: [[soreness]] at the injection site, [[urticaria]], [[dizziness]], [[nausea]], [[chills]], [[fever]], and [[insomnia]].


During multiple dose subchronic tolerance studies in normal human volunteers, the following were noted: a decrease in hemoglobin, hematocrit and creatinine clearance; elevation of alkaline phosphatase, BUN and SGPT. In single and multiple dose studies in normal volunteers, a reduction in urine output was noted. Extensive renal function studies demonstrated no consistent changes indicative of renal toxicity.
During multiple dose subchronic tolerance studies in normal human volunteers, the following were noted: a decrease in [[hemoglobin]], [[hematocrit]] and [[creatinine clearance]]; elevation of [[alkaline phosphatase]], [[BUN]] and [[SGPT]]. In single and multiple dose studies in normal volunteers, a reduction in urine output was noted. Extensive renal function studies demonstrated no consistent changes indicative of renal toxicity.


A few cases of anaphylaxis or anaphylactoid reactions have been reported. If serious allergic reactions occur, the usual agents (epinephrine, corticosteroids, and/or antihistamines) should be available for emergency use. In cases of severe anaphylaxis, airway support and oxygen may also be required.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = TROBICIN (SPECTINOMYCIN) [PHARMACIA AND UPJOHN, CO.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=becf7b7a-508c-44ff-add0-558a60fd0067 | publisher =  | date =  | accessdate = }}</ref>
A few cases of [[anaphylaxis]] or anaphylactoid reactions have been reported. If serious allergic reactions occur, the usual agents ([[epinephrine]], [[corticosteroids]], and/or [[antihistamine]]s) should be available for emergency use. In cases of severe anaphylaxis, airway support and oxygen may also be required.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = TROBICIN (SPECTINOMYCIN) [PHARMACIA AND UPJOHN, CO.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=becf7b7a-508c-44ff-add0-558a60fd0067 | publisher =  | date =  | accessdate = }}</ref>


==References==
==References==

Latest revision as of 00:55, 31 December 2013

Spectinomycin
TROBICIN® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Adverse Reactions

The following reactions were observed during the single dose clinical trials: soreness at the injection site, urticaria, dizziness, nausea, chills, fever, and insomnia.

During multiple dose subchronic tolerance studies in normal human volunteers, the following were noted: a decrease in hemoglobin, hematocrit and creatinine clearance; elevation of alkaline phosphatase, BUN and SGPT. In single and multiple dose studies in normal volunteers, a reduction in urine output was noted. Extensive renal function studies demonstrated no consistent changes indicative of renal toxicity.

A few cases of anaphylaxis or anaphylactoid reactions have been reported. If serious allergic reactions occur, the usual agents (epinephrine, corticosteroids, and/or antihistamines) should be available for emergency use. In cases of severe anaphylaxis, airway support and oxygen may also be required.[1]

References

  1. "TROBICIN (SPECTINOMYCIN) [PHARMACIA AND UPJOHN, CO.]".

Adapted from the FDA Package Insert.